BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa - 2The Incomparable Advanced cameras: Which One Will Win?
- 3Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- 410 Famous Frozen yogurt Flavors All over The Planet
- 5Figure out How to Adjust Your Handshake to Various Societies
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- The Main 15 Applications for Efficiency and Association
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- San Francisco sues 10 companies that make ultraprocessed food
- Watch This Glacier Race into the Sea
- Astounding Treehouses All over the Planet
- China's Normal Ponders: A Visual Excursion
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
